Long-Term Safety of Adalimumab in 29,967 Adult Patients From Global Clinical Trials Across Multiple Indications: An Updated Analysis

Efficacy and safety of continuing versus withdrawing adalimumab therapy in maintaining remission in patients with non-radiographic axial spondyloarthritis (ABILITY-3): a multicentre, randomised, double-blind study

(2018) Robert Landewé et al.   LANCET

Safety and Efficacy of Adalimumab in Patients with Noninfectious Uveitis in an Ongoing Open-Label Study: VISUAL III

(2018) Eric B. Suhler et al.   OPHTHALMOLOGY

Safety of Adalimumab in Pediatric Patients with Polyarticular Juvenile Idiopathic Arthritis, Enthesitis-Related Arthritis, Psoriasis, and Crohn's Disease

(2018) Gerd Horneff et al.   JOURNAL OF PEDIATRICS

Effect of Adalimumab on Clinical Outcomes and Health-related Quality of Life Among Patients With Ulcerative Colitis in a Clinical Practice Setting: Results From InspirADA

(2017) Simon Travis et al.   Journal of Crohns & Colitis

Infections in Moderate to Severe Psoriasis Patients Treated with Biological Drugs Compared to Classic Systemic Drugs: Findings from the BIOBADADERM Registry

(2017) Paula Dávila-Seijo et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Cardiovascular event risk assessment in psoriasis patients treated with tumor necrosis factor-α inhibitors versus methotrexate

(2017) Jashin J. Wu et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial

(2017) Jean-Frederic Colombel et al.   LANCET

Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease

(2017) Paul M Ridker et al.   NEW ENGLAND JOURNAL OF MEDICINE

Incidência de tuberculose em pacientes com artrite reumatoide em uso de bloqueadores do TNF no Brasil: dados do Registro Brasileiro de Monitoração de Terapias Biológicas BiobadaBrasil

(2017) Claudia Leiko Yonekura et al.   Revista Brasileira De Reumatologia

Adalimumab long-term safety: infections, vaccination response and pregnancy outcomes in patients with rheumatoid arthritis

(2016) Gerd R Burmester et al.   ANNALS OF THE RHEUMATIC DISEASES

Management of cardiovascular disease in patients with psoriasis

(2016) Alexander Egeberg et al.   EXPERT OPINION ON PHARMACOTHERAPY

Methotrexate Dosage Reduction Upon Adalimumab Initiation: Clinical and Ultrasonographic Outcomes from the Randomized Noninferiority MUSICA Trial

(2016) G. S. Kaeley et al.   JOURNAL OF RHEUMATOLOGY

Efficacy and safety of adalimumab in Chinese patients with moderate-to-severe plaque psoriasis: results from a phase 3, randomized, placebo-controlled, double-blind study

(2016) L. Cai et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial

(2016) Quan Dong Nguyen et al.   LANCET

Adalimumab in Patients with Active Noninfectious Uveitis

(2016) Glenn J. Jaffe et al.   NEW ENGLAND JOURNAL OF MEDICINE

Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa

(2016) Alexa B. Kimball et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy and Safety of Adalimumab in Canadian Patients with Moderate to Severe Crohn’s Disease: Results of the Adalimumab in Canadian SubjeCts with ModErate to Severe Crohn’s DiseaSe (ACCESS) Trial

(2016) Remo Panaccione et al.   CANADIAN JOURNAL OF GASTROENTEROLOGY

The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis

(2015) Camille Roubille et al.   ANNALS OF THE RHEUMATIC DISEASES

Drug safety of systemic treatments for psoriasis: results from The German Psoriasis Registry PsoBest

(2015) K. Reich et al.   ARCHIVES OF DERMATOLOGICAL RESEARCH

Adalimumab treatment optimization for psoriasis: Results of a long-term phase 2/3 Japanese study

(2015) Akihiko Asahina et al.   JOURNAL OF DERMATOLOGY

Randomized Controlled Trial of Adalimumab in Patients With Nonpsoriatic Peripheral Spondyloarthritis

(2015) Philip Mease et al.   Arthritis & Rheumatology

Four-Year Maintenance Treatment With Adalimumab in Patients with Moderately to Severely Active Ulcerative Colitis: Data from ULTRA 1, 2 and 3

(2014) Jean-Frederic Colombel et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Efficacy and safety of ascending methotrexate dose in combination with adalimumab: the randomised CONCERTO trial

(2014) Gerd-Rűdiger Burmester et al.   ANNALS OF THE RHEUMATIC DISEASES

Long-term safety and efficacy of adalimumab in Japanese patients with moderate to severe Crohn's disease

(2014) Mamoru Watanabe et al.   Journal of Crohns & Colitis

Clinical investigation in highly disease-affected rheumatoid arthritis patients in Japan with adalimumab applying standard and general evaluation: the CHANGE study

(2014) Nobuyuki Miyasaka et al.   Modern Rheumatology

A multicenter, open-label, efficacy, pharmacokinetic, and safety study of adalimumab in Japanese patients with ankylosing spondylitis

(2014) Shigeto Kobayashi et al.   Modern Rheumatology

Serious infections in patients with rheumatoid arthritis and other immune-mediated connective tissue diseases exposed to anti-TNF or rituximab: data from the Spanish registry BIOBADASER 2.0

(2014) Tatiana Cobo-Ibáñez et al.   RHEUMATOLOGY INTERNATIONAL

Safety and effectiveness of adalimumab in patients with rheumatoid arthritis over 5 years of therapy in a phase 3b and subsequent postmarketing observational study

(2014) Gerd R Burmester et al.   ARTHRITIS RESEARCH & THERAPY

Ankylosing Spondylitis, Psoriatic Arthritis, and Risk of Malignant Lymphoma: A Cohort Study Based on Nationwide Prospectively Recorded Data From Sweden

(2014) K. Hellgren et al.   Arthritis & Rheumatology

Adalimumab for the Treatment of Moderate to Severe Hidradenitis Suppurativa

(2013) Alexa B. Kimball et al.   ANNALS OF INTERNAL MEDICINE

Adalimumab, a human anti-TNF monoclonal antibody, outcome study for the prevention of joint damage in Japanese patients with early rheumatoid arthritis: the HOPEFUL 1 study

(2013) Tsutomu Takeuchi et al.   ANNALS OF THE RHEUMATIC DISEASES

Efficacy and safety of adalimumab in Chinese adults with active ankylosing spondylitis: results of a randomised, controlled trial

(2013) Feng Huang et al.   ANNALS OF THE RHEUMATIC DISEASES

Efficacy and safety of adalimumab in Japanese patients with moderately to severely active ulcerative colitis

(2013) Yasuo Suzuki et al.   JOURNAL OF GASTROENTEROLOGY

Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1)

(2012) Joachim Sieper et al.   ANNALS OF THE RHEUMATIC DISEASES

Difference in the risk of serious infections in patients with rheumatoid arthritis treated with adalimumab, infliximab and etanercept: results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry

(2012) Sanne A A van Dartel et al.   ANNALS OF THE RHEUMATIC DISEASES

Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease

(2012) Gerd R Burmester et al.   ANNALS OF THE RHEUMATIC DISEASES

Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA study

(2012) Arthur Kavanaugh et al.   ANNALS OF THE RHEUMATIC DISEASES

Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: Comparison of adalimumab, etanercept and infliximab in the GISEA registry

(2012) Fabiola Atzeni et al.   AUTOIMMUNITY REVIEWS

Adalimumab Induces and Maintains Mucosal Healing in Patients With Crohn's Disease: Data From the EXTEND Trial

(2012) Paul Rutgeerts et al.   GASTROENTEROLOGY

The Long-Term Safety of Adalimumab Treatment in Moderate to Severe Psoriasis

(2011) Craig Leonardi et al.   AMERICAN JOURNAL OF CLINICAL DERMATOLOGY

Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient?

(2011) A. Strangfeld et al.   ANNALS OF THE RHEUMATIC DISEASES

Treatment with tumor necrosis factor inhibitors and the risk of acute coronary syndromes in early rheumatoid arthritis

(2011) Lotta Ljung et al.   ARTHRITIS AND RHEUMATISM

Safety and effectiveness of adalimumab in a clinical setting that reflects Canadian standard of care for the treatment of rheumatoid arthritis (RA): Results from the CanACT study

(2011) Boulos Haraoui et al.   BMC MUSCULOSKELETAL DISORDERS

Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial

(2011) W. Reinisch et al.   GUT

Adalimumab produces clinical remission and reduces extraintestinal manifestations in Crohnʼs disease: Results from CARE

(2011) Robert Löfberg et al.   INFLAMMATORY BOWEL DISEASES

Adalimumab for the induction and maintenance of clinical remission in Japanese patients with Crohn's disease

(2011) Mamoru Watanabe et al.   Journal of Crohns & Colitis

Switching to adalimumab for psoriasis patients with a suboptimal response to etanercept, methotrexate, or phototherapy: Efficacy and safety results from an open-label study

(2011) Bruce E. Strober et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Long-term efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3 years: Results from an open-label extension study for patients from REVEAL

(2011) Kenneth Gordon et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Efficacy and safety of adalimumab when added to inadequate therapy for the treatment of psoriasis: results of PRIDE, an open-label, multicentre, phase IIIb study

(2011) K. Papp et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

The CHOICE trial: adalimumab demonstrates safety, fistula healing, improved quality of life and increased work productivity in patients with Crohn’s disease who failed prior infliximab therapy

(2010) S. Lichtiger et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Adalimumab sustains clinical remission and overall clinical benefit after 2 years of therapy for Crohn’s disease

(2010) R. PANACCIONE et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry

(2010) D. Salmon-Ceron et al.   ANNALS OF THE RHEUMATIC DISEASES

Adalimumab for Treatment of Moderate to Severe Chronic Plaque Psoriasis of the Hands and Feet

(2010) Craig Leonardi et al.   ARCHIVES OF DERMATOLOGY

Do rheumatoid arthritis and lymphoma share risk factors?: A comparison of lymphoma and cancer risks before and after diagnosis of rheumatoid arthritis

(2010) Karin Hellgren et al.   ARTHRITIS AND RHEUMATISM

A phase IIIb, multicentre, randomized, double-blind, vehicle-controlled study of the efficacy and safety of adalimumab with and without calcipotriol/betamethasone topical treatment in patients with moderate to severe psoriasis: the BELIEVE study

(2010) D. Thaçi et al.   BRITISH JOURNAL OF DERMATOLOGY

Adalimumab in Japanese patients with moderate to severe chronic plaque psoriasis: Efficacy and safety results from a Phase II/III randomized controlled study

(2010) Akihiko ASAHINA et al.   JOURNAL OF DERMATOLOGY

Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly

(2010) J. B. Galloway et al.   RHEUMATOLOGY

A Comparison of Patient Characteristics and Outcomes in Selected European and U.S. Rheumatoid Arthritis Registries

(2010) Jeffrey R. Curtis et al.   SEMINARS IN ARTHRITIS AND RHEUMATISM

Effectiveness and safety of adalimumab in patients with ankylosing spondylitis or psoriatic arthritis and history of anti-tumor necrosis factor therapy

(2010) Martin Rudwaleit et al.   ARTHRITIS RESEARCH & THERAPY

Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBIT

(2010) Anja Strangfeld et al.   ARTHRITIS RESEARCH & THERAPY

Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseases

(2009) G R Burmester et al.   ANNALS OF THE RHEUMATIC DISEASES

Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR)

(2009) W. G. Dixon et al.   ANNALS OF THE RHEUMATIC DISEASES

Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor α therapies: Does the risk change with the time since start of treatment?

(2009) Johan Askling et al.   ARTHRITIS AND RHEUMATISM

Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective french research axed on tolerance of biotherapies registry

(2009) F. Tubach et al.   ARTHRITIS AND RHEUMATISM

Risk of Lymphoma Associated With Combination Anti–Tumor Necrosis Factor and Immunomodulator Therapy for the Treatment of Crohn's Disease: A Meta-Analysis

(2009) Corey A. Siegel et al.   Clinical Gastroenterology and Hepatology

Increased Risk for Non-Melanoma Skin Cancer in Patients With Inflammatory Bowel Disease

(2009) Millie D. Long et al.   Clinical Gastroenterology and Hepatology

Randomized, Double-blind, Placebo-controlled, Comparative Study of Human Anti-TNF Antibody Adalimumab in Combination with Methotrexate and Methotrexate Alone in Taiwanese Patients with Active Rheumatoid Arthritis

(2009) Der-Yuan Chen et al.   JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION

Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register

(2008) J Askling et al.   ANNALS OF THE RHEUMATIC DISEASES

Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: results of a prospective open-label study

(2008) M Rudwaleit et al.   ANNALS OF THE RHEUMATIC DISEASES

Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT)

(2008) P J Mease et al.   ANNALS OF THE RHEUMATIC DISEASES

Evaluation of the patient acceptable symptom state as an outcome measure in patients with ankylosing spondylitis: Data from a randomized controlled trial

(2008) Maxime Dougados et al.   ARTHRITIS AND RHEUMATISM

Effect of the early use of the anti-tumor necrosis factor adalimumab on the prevention of job loss in patients with early rheumatoid arthritis

(2008) Victoria Bejarano et al.   ARTHRITIS AND RHEUMATISM

An open-label pilot study of the effectiveness of adalimumab in patients with rheumatoid arthritis and previous infliximab treatment: relationship to reasons for failure and anti-infliximab antibody status

(2008) Arie E. van der Bijl et al.   CLINICAL RHEUMATOLOGY

Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial

(2007) Alan Menter et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY